
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Notice of Results & Investor Presentation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, will announce its unaudited interim results for the six months ended 30 June 2026 on Tuesday 15 September.
Investor presentation
EKF Diagnostics will be hosting a live online presentation open to all existing and potential investors on Tuesday 15 September 2026 at 4.30pm (BST) via the Investor Meet Company platform.
Investors can sign up to Investor Meet Company for free and add to meet EKF Diagnostics via:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
The investor presentation will be available on the Company's website at www.ekfdiagnostics.com and a recording of the presentation and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.
|
EKF Diagnostics Holdings plc |
||
|
Gavin Jones, Chief Executive Officer |
via Walbrook PR |
|
|
Helen Jones, Chief Financial Officer |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
|
|
|
Jen Boorer / Russell Cook / Patrick Weaver |
Tel: +44 (0)20 7496 3000 |
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates four manufacturing sites across the US and Germany, selling into over 120 countries world-wide.